Blogs

Blogs

ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.

No Results.

Dr. McAneny's broad expertise and insight on today’s challenging health care environment will greatly benefit the practice of medicine and our patients.
Preparing for the future starts with gaining clarity about the present state of oncology care. Our goal is for practices in all settings across the U.S. to provide feedback in the 2017 ASCO Practice Census.
If you say things of consequence, there may be consequences; but the alternative is to be inconsequential. Particularly in these tumultuous times for health care and research, we need to speak up!
Mr. Harvey D. Bichkoff offers a firsthand perspective of MACRA implementation at Marin Cancer Care, the private practice for which he serves as CEO.
We’re making progress in better understanding, and communicating, the many issues surrounding adverse events, although not as fast as we’d like. In the long run, our patients will benefit from all of these initiatives.
Sustaining this progress described in this report will be determined in large part by the level of federal investment in our nation's biomedical research enterprise.
ASCO soundly opposes President Trump’s budget outline, which would cut $6 billion from the National Institutes of Health.
In the past 2 years, Bellevue Cancer Center's legal clinic saw more than 75 patients who were ineligible for lifesaving transplants or clinical trials due to their immigration status. Ms. Domna Antoniadis and Dr. Daniel Boxer outline the challenges faced by these patients.
Do you belong to your ASCO State/Regional Affiliate? If not, you should! Do you take advantage of all they have to offer? If not, you should! You, and more importantly your patients, will benefit enormously.
Policy issues fundamentally affect us, our practices, and most importantly, our patients. As I hope you are aware, ASCO has our backs.  Indeed, understanding and making meaningful changes to health policy has become a major focus of ASCO.  
We (the ASCO delegation) have just returned from the interim American Medical Association (AMA) House of Delegates meeting in Orlando. ASCO proposed a resolution focused on the restrictive opioid policies being adopted by many states. Many of the state legislations include language restricting...
Vice President Joe Biden and the government-wide Cancer Moonshot Task Force have presented today a sweeping vision that, if realized, could change the face of cancer prevention, screening, treatment, and survivorship as we know it.
Many of the successful, FDA-approved drugs commonly used in cancer care were developed at small biotech or pharma companies—so what role do the "big fish" play?
Support for federal research funding for cancer is not about politics. It's about people. There is no one in our society—liberal, conservative, libertarian, or just don’t care—who isn’t touched in some way by cancer.
Believe it or not, the Medicare Access and CHIP Reauthorization Act of 2015 was passed more than 1 year ago, and program changes begin in less than six months, on Janurary 1, 2017.
Nurse-led patient navigation services are clearly valuable. A study being presented at #ASCO16 may provide enough evidence of a survival benefit to make these services reimbursable.
This is the story of how, like Mr. Smith in Washington, the medical community in Brazil gathered to speak truth to power about the lack of evidence for phosphoethanolamine as a cancer treatment.
ASCO commends the FDA for exercising its congressionally mandated authority to regulate cigars, hookah tobacco, electronic cigarettes (e-cigarettes), and other electronic nicotine delivery systems (ENDS), a crucial step in further regulating deadly tobacco products.

Pages